Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- N/A
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1
HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
- Status
- RECRUITING
- Phase
- PHASE3
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1
Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT
- Status
- WITHDRAWN
- Phase
- NA
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC
- Status
- UNKNOWN
- Phase
- PHASE2
Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension
- Status
- COMPLETED
- Phase
- PHASE3
Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- NA
Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)
- Status
- UNKNOWN
- Phase
- PHASE2
Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis
- Status
- UNKNOWN
- Phase
- PHASE2
Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- NA
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2